Rising

United States 319 employees Updated 9 July 2026

Rising is an API and finished-dose manufacturer based in United States. It holds 2 active US drug master files across a filed portfolio of 2 molecules. Its filings concentrate with US FDA and DMP (NO). Its most recent recorded inspection, by US FDA, closed on 8 April 2022 as VAI.

active US DMFs

valid CEPs

registered plants 1 with an FDA FEI number

606

filings across 2 regulators

These figures were checked against the regulators' own files on 25 July 2026

Plants

1 of 1 confirmed

Inspections

8 of 8 confirmed

Sources: FDA Establishment Registration, read 4 May 2026. FDA drug inspection classifications, read 4 May 2026.

Inspection history

8 April 2022 VAI US FDA
16 May 2018 OAI US FDA
9 December 2016 NAI US FDA
10 June 2016 OAI US FDA
6 June 2014 VAI US FDA
3 May 2013 OAI US FDA
26 October 2012 VAI US FDA
25 May 2012 NAI US FDA

NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.

Registered plants

Site	FDA FEI
Coimbra, Portugal	Not on file
Decatur, United States	1419498

What they file, and where

Molecule	Regulators	Docs
Colestipol	US FDA	1
Metaxalone	US FDA	1

Also appears on these molecule pages

Abiraterone finished dose Anagrelide finished dose Azathioprine finished dose Benazepril finished dose Benzoyl Peroxide finished dose Bisoprolol finished dose Bumetanide finished dose Buspirone finished dose Calcitriol finished dose Captopril finished dose Cefixime finished dose Chlorothiazide finished dose

Show 62 more molecule pages

Filings and GMP by regulator

Regulator	Filings	GMP certificates
US FDA	604	None
DMP (NO)	2	None

Questions about Rising

Does Rising hold a US DMF or a CEP?

Rising holds 2 active US drug master files. A drug master file is a submission to the FDA describing how an ingredient is made; a CEP is the EDQM's certificate that the substance meets its European Pharmacopoeia monograph. Both are filings rather than approvals.

Is Rising FDA-registered?

One site operated by Rising carries an FDA establishment identifier (FEI), which means it is registered with the FDA as a drug establishment. Registration is not the same as approval or inspection clearance.

How did Rising's last inspection go?

The most recent inspection on record closed on 8 April 2022 as VAI (Voluntary Action Indicated: issues were found but did not warrant regulatory action). 8 inspections are on file, of which 3 closed as OAI.

Where does Rising manufacture?

2 registered sites are on record, in Portugal and United States (Coimbra and Decatur). Every site is listed on this page with the register it came from.

What does Rising make?

2 molecules are on record against Rising, including Colestipol and Metaxalone. Each links through to that molecule's full manufacturer list.

Where does Rising file?

Filings are on record with US FDA and DMP (NO), 606 in total.

Answered from this company's own record. Where a register holds nothing, the question is not asked rather than answered with a zero. How we count our figures.

Comparing suppliers?

Choose your molecules and target markets. Rising comes back tiered against every other supplier able to file there.

Start for free

No sales call.

Open risk flags

99 active litigation matters are on record.
The most recent inspection outcome was VAI, on 8 April 2022.

Comparable suppliers

Raks Pharma shares 2 molecules Hetero shares 1 molecule Zydus Lifesciences shares 1 molecule Cohance Lifesciences shares 1 molecule Solara Active Pharma Sciences shares 1 molecule

Ranked by shared active ingredients where we have them, otherwise by country and comparable credentials.

Sources on this page

FDA: Drug master files, establishment registration, inspection classifications
EDQM: Certificates of suitability